Improving drug delivery for osteoarthritis
Intra-cartilage depot delivery of electrically-charged IL-1RA for targeting osteoarthritis-associated inflammation and catabolism in multiple joint tissues
This project is developing a new way to deliver medicine directly into joint cartilage to better treat pain and damage from osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northeastern University NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11141621 on NIH RePORTER |
What this research studies
Current treatments for osteoarthritis often don't reach deep enough into the joint cartilage or stay long enough to be truly effective. This project aims to overcome this challenge by using a special electrically-charged medicine that can penetrate the dense cartilage and stay there longer. By delivering the medicine directly to the affected areas, we hope to reduce inflammation and slow down the breakdown of cartilage in multiple parts of the joint. This approach could make treatments much more effective for people living with osteoarthritis.
Who could benefit from this research
Good fit: Patients with osteoarthritis who experience joint pain and cartilage damage, particularly those for whom current treatments are not fully effective, are the target beneficiaries of this research.
Not a fit: Patients without osteoarthritis or those whose joint issues are not related to cartilage breakdown may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new delivery method could lead to more effective treatments that slow or stop the progression of osteoarthritis, offering significant relief and improved joint function.
How similar studies have performed: While the specific electrically-charged delivery method is novel, the drug (IL-1RA) has shown promise in preclinical models for osteoarthritis, but its clinical success has been limited by delivery issues.
Where this research is happening
Boston, United States
- Northeastern University — Boston, United States (Active)
Researchers
- Principal investigator: Bajpayee, Ambika Goel — Northeastern University
- Study coordinator: Bajpayee, Ambika Goel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.